Skip to main content
Matrix One>Blog>EU Regulation 2021/2226 and 2025/1234: What Changed and What It Means for Your Device

EU Regulation 2021/2226 and 2025/1234: What Changed and What It Means for Your Device

Last updated on

EU Regulation 2021/2226 and 2025/1234 are the two Commission Implementing Regulations that decide when a medical device may ship with electronic instructions for use (eIFU) instead of paper. Short answer: since 16 July 2025, any device under Article 1(4) of the MDR that is intended for professional users may replace its paper IFU with eIFU (Article 3(1) as replaced). The manufacturer must document an eleven element risk assessment (Article 4(1)), send paper free of charge within 7 calendar days of a request (Article 5(3)) and, since 28 May 2026, give the eIFU web address to the EUDAMED UDI database (Article 7(3)). The amendment also deleted Articles 5(12), 6(4), 7(2)(f) and 8. Matrix eIFU is the eIFU hosting service we build for exactly this job.

A disclosure before the detail: I work at Matrix One, the company behind Matrix eIFU (formerly Dokspot). This page explains the law and does not rank vendors. Every article number below was checked against the EUR-Lex text of both regulations on 3 November 2026, and the EUDAMED dates against the European Commission's own EUDAMED pages on the same day.

Regulation (EU) 2021/2226 was adopted on 14 December 2021 under Article 5(6) of the MDR and published in the Official Journal on 15 December 2021. Regulation (EU) 2025/1234 was adopted on 25 June 2025, published on 26 June 2025 and entered into force on the twentieth day after publication, which is 16 July 2025. There is one rulebook, 2021/2226, and 2025/1234 rewrites parts of it.

What did Regulation 2025/1234 change, article by article?

Regulation (EU) 2025/1234 has a single operative article. Article 1 makes eight amendments to 2021/2226, and these are the ones that change what a manufacturer has to do:

Provision of 2021/2226Before 16 July 2025After 2025/1234
Article 1, third subparagraphAnnex XVI products were excluded.Deleted. Annex XVI products for professional use are in scope (recital 4).
Article 3(1)Only implantables, fixed installed devices and devices with a built-in IFU display.Any device under MDR Article 1(4) intended for use by professional users.
Article 3(2)Exclusive professional use, and use by others not reasonably foreseeable.If lay use is reasonably foreseeable, the lay instructions stay on paper.
Article 5(12)Inform users who downloaded the IFU of updates and corrective actions.Deleted.
Article 5(13)All historical versions on the website.All versions and dates kept during the retention period; obsolete versions may be given on request.
Article 6(4)Patient part of an implant IFU could not be electronic.Deleted. Article 3(2) now carries the lay user test.
Article 7(2)(f)Previous versions and publication dates on the website.Deleted, folded into Article 5(13).
Article 7(3)Did not exist.New: the eIFU address goes to the UDI database under MDR Annex VI Part B point 22.
Article 8Notified body reviews Articles 4 to 7 during conformity assessment.Deleted as redundant with MDR conformity assessment (recital 7).
Article 9, second paragraphSupplementary eIFU websites met Article 7(2)(b), (d), (e) and (f).Deleted. Only the consistency duty remains.

Recital 2 of 2025/1234 gives the reason for the change: a Commission survey run from 1 August to 10 October 2024 found a clear preference among healthcare professionals for electronic instructions over paper.

Which devices can drop the paper IFU under Article 3?

Under Article 3(1) as replaced, a manufacturer may provide instructions in electronic form instead of paper for any device referred to in Article 1(4) of Regulation (EU) 2017/745 that is intended for use by professional users. Article 2(2) defines professional users as persons using the device in the course of their work in the framework of a professional healthcare activity.

Recital 3 confirms that legacy devices under the MDR Article 120 transitional provisions are covered, and recital 4 brings in Annex XVI products without an intended medical purpose when they are meant for professional use. The old device category list (implantables, fixed installed devices, devices with a built-in display) no longer limits eligibility.

Article 3(3) is unchanged: software covered by the MDR may provide its instructions through the software itself instead of on paper.

What happens when lay persons might also use a professional device?

The replaced Article 3(2) says that where it is reasonably foreseeable that a device intended for professional users is also used by lay persons, the instructions intended for lay persons must be provided on paper. This replaced the old implant specific rule in Article 6(4), which 2025/1234 deleted. In practice a clinician-facing IFU can go electronic while a patient leaflet for the same device stays printed.

Does Regulation 2021/2226 cover IVDs?

No. It is adopted under Article 5(6) of the MDR and its scope is devices covered by Regulation (EU) 2017/745. In vitro diagnostic devices fall under Regulation (EU) 2017/746, which 2021/2226 does not implement. See our eIFU page for IVDR manufacturers for that route.

What must the Article 4 risk assessment cover?

Article 4(1) requires a documented risk assessment before replacing paper, covering at least these eleven elements. Article 4(2) requires it to be updated with post-market experience, and Article 5(1) sets the pass mark: electronic instructions must maintain or improve the level of safety that paper provided.

Article 4(1) pointWhat the assessment must cover
(a)Knowledge and experience of the intended users, including user needs.
(b)Characteristics of the environment where the device is used.
(c)Users' knowledge of the hardware and software needed to display the eIFU.
(d)Access to the electronic resources reasonably needed at the time of use.
(e)Safeguards protecting the electronic content from tampering.
(f)Safety and back-up mechanisms if hardware or software fails.
(g)Foreseeable medical emergencies that need information on paper.
(h)Impact of the website or internet being temporarily unavailable.
(i)The period within which paper is supplied on request.
(j)Website compatibility with the devices used to display the eIFU.
(k)Management of different IFU versions, linked to Article 5(8).

What are the Article 5 conditions for going paperless?

Article 5 lists the operating conditions a manufacturer must meet once the risk assessment supports eIFU. 2025/1234 deleted point (12) and rewrote point (13); the rest stands as adopted in 2021.

Article 5 pointWhat it requires
(2)eIFU in every Member State where the device is made available, unless the risk assessment duly justifies otherwise.
(3)Paper at no additional cost within the assessed period, at the latest 7 calendar days after a request, or at delivery if asked for at order.
(4)Emergency information on the device or a leaflet, plus start-up information for built-in displays.
(5)Proper design and functioning of the eIFU, with verification and validation evidence.
(7)Software and hardware requirements for viewing, stated in the catalogue or device information.
(8)A system that shows when the IFU was revised and informs users if the revision was for safety reasons.
(9)Devices with an expiry date: available 10 years after the last device is placed on the market and at least 2 years past the last expiry date.
(10)Implantables and devices with no expiry date: available 15 years after the last device is placed on the market.
(11)On the website in an official EU language determined by the Member State where the device is made available.
(13)All issued versions and their publication dates during those periods; obsolete versions may be made available on request.

What must the label and the website do under Articles 6 and 7?

Article 6(1) requires the label to state clearly that the IFU is supplied in electronic form instead of paper, on the packaging for each unit or, where appropriate, the sales packaging. Fixed installed devices also carry it on the device itself, and software shows it where access to the software is granted.

Article 6(3) says the access information must include whatever is needed to view the IFU, the Basic UDI-DI and/or UDI-DI, the manufacturer's contact details, and where and how to request paper and within what time. Article 6(5) requires the eIFU to be available entirely as text, with symbols and graphics allowed; video or audio may only be added on top.

Article 7(1) adds that eIFU supplied on a storage medium or a built-in display must also be on a website. Article 7(2) sets the website rules: a commonly used format readable with free software (a), protection against unauthorised access and tampering (b), downtime and display errors reduced as far as possible (c), compliance with the GDPR (d), and an internet address that stays stable and directly accessible for the Article 5(9) and (10) periods (e).

When does the eIFU address have to be in EUDAMED?

Article 7(3), added by 2025/1234, requires the manufacturer to give the Article 7(2)(e) address to the UDI database under Part B, point 22 of MDR Annex VI, at the latest by the date device registration applies under MDR Article 123(3), point (d) or (e).

That date is now fixed. Commission Decision (EU) 2025/2371 was published on 27 November 2025, which started a six month transition, and the European Commission's EUDAMED page confirms the Actor, UDI/Device, Notified Bodies and Certificates, and Market Surveillance modules have been mandatory since 28 May 2026.

Devices whose first unit was placed on the market before 28 May 2026 get a longer window. The Commission's transition timeline for legacy and Regulation devices sets 28 November 2026 as the deadline to register them in the UDI/Device module, so any manufacturer using eIFU instead of paper on an existing device has until that date to put the eIFU address in its EUDAMED record. Our EUDAMED registration guide walks through the field itself.

Does supplementary eIFU, provided alongside paper, still have rules?

Very few. Article 9 now says only that eIFU provided in addition to complete paper instructions must be consistent with the paper content. Its second paragraph, which applied the Article 7(2) website rules to those sites, was deleted by Article 1 point (8) of 2025/1234. The Article 4 risk assessment and the Article 5 conditions apply to manufacturers providing eIFU instead of paper, not to a manufacturer that still ships complete paper.

Which pathway fits your device: eIFU instead of paper or alongside it?

FactoreIFU alongside complete paper (Article 9)eIFU instead of paper (Articles 3 to 7)
Who may use itAny device.Devices for professional users; lay instructions stay on paper.
Risk assessmentNot required by 2021/2226.Article 4(1), eleven elements, updated post-market.
Paper on requestPaper already ships.Free, at the latest within 7 calendar days (Article 5(3)).
Label statementNot required.Article 6(1) statement plus Article 6(3) access information.
Website rulesConsistency with paper only.Article 7(2) points (a) to (e).
EUDAMED addressNo duty under 2021/2226.Article 7(3), Annex VI Part B point 22.

Many manufacturers start with eIFU alongside paper to run the website and the paper request process before they change packaging. That is a sequencing choice, not a legal requirement.

How did the EU eIFU rules get here?

DateMilestoneWhy it matters
9 March 2012Regulation (EU) No 207/2012 adoptedeIFU rules for devices under the old directives 90/385/EEC and 93/42/EEC.
5 April 2017MDR 2017/745 adoptedIts Article 5(6) is the legal basis for the later eIFU implementing rules.
14 December 2021Regulation (EU) 2021/2226 adoptedRepeals 207/2012 (Article 10) with the narrow Article 3 device list.
26 May 2024207/2012 stops applyingIts last use, for Article 120(3) devices, ends under Article 10.
1 August to 10 October 2024Commission surveyHealthcare professionals prefer electronic IFU (recital 2 of 2025/1234).
16 July 2025Regulation (EU) 2025/1234 in forceOpens eIFU to all professional-use devices and deletes four duties.
27 November 2025Decision (EU) 2025/2371 publishedFirst four EUDAMED modules declared functional.
28 May 2026EUDAMED modules mandatoryNew registrations carry the Article 7(3) eIFU address.
28 November 2026Registration deadline for devices already on the marketLast date to register devices first placed before 28 May 2026.

What does this mean for a professional-use device sold across the EU?

For a manufacturer moving a professional-use MDR device from paper to eIFU across the EU, the order of work that follows from the articles is:

  1. Confirm the device is intended for professional users and decide which instructions lay persons could foreseeably need on paper (Article 3(2)).

  2. Write the eleven element risk assessment and show eIFU maintains or improves safety (Articles 4(1) and 5(1)).

  3. Fix the content as complete text in each required language, with any video as an addition (Articles 5(11) and 6(5)).

  4. Choose a website that meets Article 7(2), with an address that will stay stable for 10 or 15 years.

  5. Change the label and access information, including the Basic UDI-DI and the paper request route (Article 6).

  6. Put the paper request process live with a 7 calendar day ceiling (Article 5(3)).

  7. Register the eIFU address in EUDAMED: at registration for new devices, by 28 November 2026 for devices already on the market (Article 7(3)).

Where does Matrix eIFU fit, and what would you run alongside it?

Matrix eIFU is a white label electronic instructions for use service for medical device and IVD manufacturers: users reach the instructions on the manufacturer's own branded site in three clicks. Plans start at 420 euros a month for three product lines, with unlimited products and IFU documents, according to the Matrix eIFU product page.

It maps to the articles above through its modules: audit logs, change records, an approval process, paper orders, version management, website translations and geo-fencing. It ships templates for the eIFU quality assurance processes, including software and system validation reports, is developed under an ISO 9001 certified quality management system, and support averages a one hour response. The EU MDR compliance page and the EUDAMED readiness page cover the UDI linking and paper on demand side.

What you would run alongside it is the artwork and labelling system that produces the label carrying the Article 6 statement. Artwork and label management is the core strength of platforms such as Kallik, while Matrix eIFU hosts and versions the instructions the label points to. For the vendor comparison, see our best eIFU software ranking, the eIFU hosting providers comparison and the IFU management software comparison.

Where can you read more?

Summary: what did EU Regulation 2021/2226 and 2025/1234 change for eIFU?

EU Regulation 2021/2226, as amended by 2025/1234 from 16 July 2025, lets any MDR device intended for professional users replace paper instructions with eIFU, provided the manufacturer documents the eleven element Article 4(1) risk assessment, keeps paper available free within 7 calendar days, meets the Article 6 labelling and Article 7(2) website rules, and gives the eIFU address to EUDAMED under Article 7(3). The amendment deleted the device category list, the update notification duty, the separate notified body review and the website rules for supplementary eIFU. Matrix eIFU is the hosting service we build to run that process. The three things that matter most:

  1. Eligibility now turns on professional use, not device type (Article 3(1) as replaced).

  2. Paper stays a right: free, at the latest within 7 calendar days of a request (Article 5(3)).

  3. The eIFU address belongs in EUDAMED: at registration since 28 May 2026, and by 28 November 2026 for devices already on the market (Article 7(3)).

For which eIFU platforms do this best, see our best eIFU software ranking.

Last updated: 3 November 2026.

EU eIFU regulation: frequently asked questions

Is eIFU now allowed for every professional-use medical device?

Yes, for devices under the MDR. Since 16 July 2025, Article 3(1) of Regulation (EU) 2021/2226 as replaced allows electronic instructions instead of paper for any device referred to in Article 1(4) of Regulation (EU) 2017/745 that is intended for professional users. The manufacturer still has to pass the Article 4 risk assessment and meet the Article 5 conditions, and where lay use is reasonably foreseeable the lay instructions stay on paper under Article 3(2).

How fast must a paper IFU be sent when a user asks for one?

Article 5(3) requires a system that supplies the paper IFU at no additional cost within the period set in the risk assessment, and at the latest within 7 calendar days of receiving the request. If the user asks at the time of order, the paper must come with the device at delivery. 2025/1234 did not change this point.

Do we still have to keep every old IFU version online?

Not every one. Article 5(13) as replaced by 2025/1234 requires all issued electronic versions and their publication dates to be available on the website during the Article 5(9) and (10) retention periods, but obsolete versions may instead be made available on request. Article 7(2)(f), which repeated the old duty, was deleted.

Does a notified body still have to review our eIFU?

Not under a separate eIFU article. 2025/1234 deleted Article 8 of 2021/2226, which had required the notified body to review Articles 4 to 7 during conformity assessment. Recital 7 explains that the information supplied by the manufacturer is already part of conformity assessment under the MDR, so the review now happens there rather than under the eIFU regulation.

What is the EUDAMED deadline for the eIFU address on devices already on the market?

28 November 2026. Article 7(3) ties the eIFU address to UDI database registration under MDR Article 123(3), point (d) or (e). The first four EUDAMED modules have been mandatory since 28 May 2026, and the European Commission's transition timeline gives devices first placed on the market before that date until 28 November 2026 to be registered in the UDI/Device module.

Can an eIFU be a video?

Only as an addition. Article 6(5) of Regulation (EU) 2021/2226 requires electronic instructions to be available entirely as text, which may contain symbols and graphics, with at least the same information as the paper version. Video or audio files may be provided in addition to the text, never instead of it.

Does eIFU provided alongside paper need a risk assessment?

Not under 2021/2226. The Article 4 risk assessment applies to manufacturers providing electronic instructions instead of paper. When complete paper instructions ship with the device, Article 9 only requires the electronic version to be consistent with the paper one, and since 2025/1234 deleted its second paragraph, the Article 7(2) website rules no longer apply to that case.

Does the eIFU regulation apply to in vitro diagnostic devices?

No. Regulation (EU) 2021/2226 is adopted under Article 5(6) of the MDR and applies to devices covered by Regulation (EU) 2017/745. IVDs fall under Regulation (EU) 2017/746, so their electronic instructions follow that regulation instead.

Written by
Eva Kautenburger
CCO

Eva Kautenburger is Chief Customer Officer at Matrix One, where she leads Customer Success & Supp across the full portfolio of regulatory and quality management solutions for the medical device industry. A certified I. and II. Party Auditor with deep expertise in ISO 13485, EU MDR/IVDR, IEC 62304, and 21 CFR Part 820, she brings both the technical fluency and regulatory grounding that MedTech customers need to navigate complex compliance landscapes. In her role, Eva oversees a cross-functional team of Solution Consultants, Solution Engineers and Account Managers, driving onboarding, retention, support and strategic growth for customers ranging from emerging device companies to global enterprises as well as consulting intiatives to support customers in their regulatory journey.

View profile →

Request a demo and get started today.

See how Matrix One connects your requirements, risks, tests, and documentation in one platform.

Request A Demo Today

Thank you

A member of our team will be in contact within 48 hours.